imageRUNNER ADVANCE C3500i III Series

Designed for small and medium workgroups or enterprises, the imageRUNNER ADVANCE (iR-ADV) C3500i III series is compact in size but big in features. Designed with intuitiveness, connectivity and quality colour prints, the iR-ADV C3500i III series delivers optimal performance for your workplace.
View Product

News & Press Release

Boost Your Design and Creative Needs with Canon’s imagePROGRAF TA Series and PosterArtist Lite

03 Jul 2020 — With a longstanding vision to boost business productivity, Canon announced the newest addition to their fleet of Large Format Printers, the Canon imagePROGRAF TA-5200 and 5300 series that comes with free Canon PosterArist Lite. Perfectly suited for CAD, design and creative businesses, the printers produce high quality posters, artworks, production supplies and advertising materials that are also perfectly suitable to cater to a variety of enterprises outside of the creative space.  “As we slowly begin to ease into normalcy, we want to be able to cater to a number of businesses, which includes the architecture, engineering, creative and design, and marketing industries, but augmenting entrepreneurs and start ups, who are searching for the right tools and products that will help boost their businesses and production needs. It is a befitting time to introduce products, such as the Canon imagePROGRAF TA Series, that will help businesses and enterprises now that we are all working to recover from the global business disruption caused by the pandemic,” said Kazuhiro Ozawa, Canon Marketing (Philippines), Inc. President & CEO.

Read More
Canon becomes a founding member of intellectual property partnership to combat spread of COVID-19

Canon becomes a founding member of intellectual property partnership to combat spread of COVID-19

04 May 2020 — In order to stop the spread of COVID-19, there is an urgent need for business, government and academia to overcome existing barriers and join forces, free from established mindsets, to accelerate development and manufacturing in such fields as therapeutic drugs, vaccines, medical devices and infection control products. Entities who become signatories of the COVID-19 Countermeasure Declaration pledge that they will not assert their patents, utility models, designs or copyrights during the time of this crisis against any activities whose purpose is stopping the spread of COVID-19, including diagnosis, prevention, containment and treatment. By eliminating the need for complicated, time-consuming analysis of intellectual property rights of the declarers and license negotiations for such intellectual property rights, this declaration clears the way for the fastest possible means of research, development and manufacture of the most effective tools to combat the spread of COVID-19. A large number of entities possessing substantial patent portfolio and industry organizations have joined the declaration in response to the invitation by Professor Fumihiko Matsuda of Kyoto University and Canon. The founding members of the declaration welcome other intellectual property rights owners to join them and further contribute to the goal of halt the spread of COVID-19. IP OPEN ACCESS DECLARATION AGAINST COVID-19 website: https://www.gckyoto.com/covid-2

Rapid Genetic Testing System for the Novel Coronavirus (SARS-CoV-2) Jointly Developed by Canon Medical Systems Corporation and Nagasaki University Now Available for Practical Application in Government-Conducted Testing

26 Mar 2020 — Canon Medical Systems Corporation (Headquarters: Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi), working together with Nagasaki University, has completed development of Genelyzer KIT 1 a set of reagents for SARS-CoV-2 RNA testing based on a gene amplification technique known as the fluorescent LAMP method. 2 The results of validation of the rapid genetic testing system employing this technique were released in a report titled "Validation of 2019-nCoV gene testing method in which clinical evaluation results were obtained using clinical specimens" 3 issued on March 26, 2020, by the Ministry of Health, Labour and Welfare and the National Institute of Infectious Diseases of Japan. This report showed a specificity of 100% and a sensitivity of 90% or more. Based on an administrative notification issued by the Ministry of Health, Labour and Welfare, 4 the rapid genetic testing system has been granted approval for practical application in government-conducted testing. In positive specimens, the testing system can detect 15 or more viral genome copies per reaction within approximately 10 minutes with 100% sensitivity. The entire test procedure, from preprocessing the sample to obtaining the test results, can be completed in as little as 40 minutes, which is much less than the time required for conventional genetic testing methods. In order to take full advantage of the testing system's rapid testing capabilities, Canon Medical Systems Corporation will continue evaluating its practical application in public health protection and border control measures at clinical sites, airports, and other locations where testing needs to be completed on the same day. This research project is part of a research program focusing on risk evaluation of emerging and re-emerging infectious diseases and the implementation of emergency management functions which is being conducted under Health and Labour Science Research Grants. Together with Nagasaki University, Canon Medical Systems Corporation is participating in a research project on the practical application of rapid genetic testing systems led by the Japan Agency for Medical Research and Development (AMED) and has been working on the development of this testing system since receiving a request for cooperative development of a testing system from the National Institute of Infectious Diseases of Japan in February 2020. The testing system has now quickly entered the practical application phase under the framework of industry-academia-government collaboration with the support of the Ministry of Health, Labour and Welfare of Japan and other involved parties. Canon Medical Systems Corporation hopes that the testing system will be used at a wide range of clinical sites in Japan to help control the spread of coronavirus disease 2019 (COVID-19). At the same time, our goal is to contribute to the development of effective measures against the spread of infectious diseases in all parts of the world using this rapid genetic testing system developed in Japan. 1 This testing system makes it possible to quickly detect a novel coronavirus gene in patient specimens. The entire procedure, including extraction of the viral genome prior to testing, can be completed in a short time of 40 minutes or less. Due to the light weight, compact design, and ease of operation of the testing system, it is suitable for use at a wide range of clinical sites, including remote locations such as isolated islands. 2 A nucleic acid amplification method known as LAMP (loop-mediated isothermal amplification) developed by Eiken Chemical Co., Ltd. 3 https://www.niid.go.jp 4 Administrative notification issued on March 18, 2020, by the Tuberculosis and Infectious Diseases Control Division, Health Services Bureau, Ministry of Health, Labour and Welfare of Japan (Method for 2019-nCoV gene testing in government-conducted testing)  

Canon Continues Charitable Cause with the Philippine Red Cross in Aid of the Victims of the Batanes Earthquake

Canon Continues Charitable Cause with the Philippine Red Cross in Aid of the Victims of the Batanes Earthquake

11 Oct 2019 — The Canon group of companies in the Philippines -- Canon Marketing Philippines, Inc. (CMPI), Canon Information Technologies Inc., Canon Business Machines Philippines, and Canon Business Service Centre Philippines (CBSCP) donated PHP 270,000 to Philippine Red Cross (PRC) to aid the victims of the 5.9 magnitude earthquake that struck Batanes last July 2019.